A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

NCT07010419 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

338

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
Adjuvant Treatment

Interventions

DRUG: Firmonertinib
DRUG: Placebo

Sponsor

Allist Pharmaceuticals, Inc.

Collaborators

[object Object]